Compare BSRR & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | BSRR | NMRA |
|---|---|---|
| Founded | 1977 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 479.7M | 554.0M |
| IPO Year | 2001 | 2023 |
| Metric | BSRR | NMRA |
|---|---|---|
| Price | $33.17 | $2.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $38.50 | $6.57 |
| AVG Volume (30 Days) | 38.0K | ★ 750.9K |
| Earning Date | 04-27-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.10% | N/A |
| EPS Growth | 10.28 | ★ 57.85 |
| EPS | ★ 3.11 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.74 | N/A |
| Revenue Next Year | $3.63 | N/A |
| P/E Ratio | $10.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.42 | $0.62 |
| 52 Week High | $38.60 | $3.65 |
| Indicator | BSRR | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 41.64 | 32.03 |
| Support Level | $32.93 | $1.78 |
| Resistance Level | $34.71 | $2.58 |
| Average True Range (ATR) | 1.09 | 0.19 |
| MACD | 0.07 | -0.09 |
| Stochastic Oscillator | 57.35 | 4.44 |
Sierra Bancorp is a California-based bank holding company, which offers a range of retail and commercial banking services. it offers a wide range of deposit products and services for individuals and businesses including checking accounts, savings accounts, money market demand accounts, time deposits, retirement accounts, and sweep accounts. The company's lending activities cover real estate, commercial (including small business), mortgage warehouse, agricultural and consumer loans, and also offers commercial construction loans and multifamily and agricultural credit facilities among other types of real estate loans.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.